Compare Stocks → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABIONASDAQ:ACHVNASDAQ:NYMX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABIOARCA biopharma$1.76+0.6%$1.66$1.56▼$2.16$25.52M1.1626,728 shs9,001 shsACHVAchieve Life Sciences$4.55+0.7%$4.50$3.03▼$10.30$95.67M1.32180,570 shs124,702 shsNYMXNymox Pharmaceutical$0.34$0.17▼$0.74$18.10M0.6494,622 shs932,700 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABIOARCA biopharma+0.57%-1.12%+4.14%+3.53%-12.44%ACHVAchieve Life Sciences+0.55%-1.20%+1.00%+10.32%-23.87%NYMXNymox Pharmaceutical0.00%0.00%0.00%0.00%-42.86%the most reliable asset on earth is making a comeback (Ad)Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click HereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABIOARCA biopharmaN/AN/AN/AN/AN/AN/AN/AN/AACHVAchieve Life Sciences1.3614 of 5 stars3.52.00.00.02.30.00.6NYMXNymox PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABIOARCA biopharmaN/AN/AN/AN/AACHVAchieve Life Sciences3.00Buy$16.33259.37% UpsideNYMXNymox PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsLatest ABIO, NYMX, and ACHV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024ACHVAchieve Life SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $11.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABIOARCA biopharmaN/AN/AN/AN/A$2.89 per shareN/AACHVAchieve Life SciencesN/AN/AN/AN/A$0.46 per shareN/ANYMXNymox PharmaceuticalN/AN/AN/AN/A($0.01) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABIOARCA biopharma-$5.34M-$0.37N/A∞N/AN/A-13.80%-13.33%4/22/2024 (Estimated)ACHVAchieve Life Sciences-$42.35M-$2.10N/AN/AN/AN/A-632.85%-136.78%N/ANYMXNymox Pharmaceutical-$6.58M-$0.04N/AN/AN/AN/A-1,589.50%-117.25%N/ALatest ABIO, NYMX, and ACHV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/1/2024Q4 2023ABIOARCA biopharmaN/A-$0.08-$0.08-$0.08N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABIOARCA biopharmaN/AN/AN/AN/AN/AACHVAchieve Life SciencesN/AN/AN/AN/AN/ANYMXNymox PharmaceuticalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABIOARCA biopharmaN/A59.0159.01ACHVAchieve Life Sciences4.025.365.36NYMXNymox PharmaceuticalN/A0.190.19OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABIOARCA biopharma56.44%ACHVAchieve Life Sciences33.52%NYMXNymox Pharmaceutical1.14%Insider OwnershipCompanyInsider OwnershipABIOARCA biopharma30.90%ACHVAchieve Life Sciences2.00%NYMXNymox Pharmaceutical54.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABIOARCA biopharma414.50 million10.02 millionOptionableACHVAchieve Life Sciences2021.17 million20.74 millionOptionableNYMXNymox Pharmaceutical390.51 million41.64 millionOptionableABIO, NYMX, and ACHV HeadlinesSourceHeadlineLatest challenges in pharmaceutical tradepharmaphorum.com - February 16 at 10:02 PMNymox December 27 Message to Shareholdersmarkets.businessinsider.com - December 27 at 8:40 PMNymox Pharmaceutical Corporation: Nymox December 27 Message to Shareholdersfinanznachrichten.de - December 27 at 3:40 PMNymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Othersfinance.yahoo.com - November 30 at 2:48 PMNymox Pharmaceutical Corporation: $250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California Courtfinanznachrichten.de - November 22 at 2:45 PM$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California Courtmarkets.businessinsider.com - November 21 at 2:24 PMNymox drama heightens as biotech sues AscellaHealth for $250M in damagesfiercebiotech.com - November 10 at 3:37 PMNymox Pharmaceutical Corporation Sues AscellaHealth For $250 Millionmarkets.businessinsider.com - November 9 at 12:34 PMThe Committee to Restore Nymox Shareholder Value Provides Factual Update to Nymox Shareholders Regarding Special Meetingfinance.yahoo.com - November 6 at 10:30 AMNYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023financialpost.com - November 3 at 11:00 AMNotice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meetingbenzinga.com - October 27 at 8:30 PMNymox Pharmaceutical Corporation: Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Reviewfinanznachrichten.de - October 26 at 12:44 PMThe Committee to Restore Nymox Shareholder Value Sends Letter to Nymox Pharmaceutical Shareholders and Issues Proxy Materials for Upcoming Special Meetingaa.com.tr - October 24 at 6:13 PMThe Committee to Restore Nymox Shareholder Value Issues Notice of Special Meeting of Nymox Pharmaceutical Shareholdersfinance.yahoo.com - October 11 at 6:04 PMBahamas Supreme Court Rules in Favor of Committee…pharmiweb.com - October 6 at 1:32 AMBahamas Supreme Court Rules in Favor of Committee to Restore Nymox Shareholder Value: Orders Shareholder Meeting, Grants Injunction Freezing CEO Sharesbusinesswire.com - October 6 at 1:32 AMNymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX ...bakersfield.com - September 27 at 7:47 PMNymox Pharmaceutical Corporation (NYMXF)finance.yahoo.com - September 26 at 11:43 PMNymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPHmarkets.businessinsider.com - September 25 at 12:31 PMNymox Reports Completion of $2 Million Private Placementmarkets.businessinsider.com - August 29 at 3:42 PMNymox Pharmaceutical Corporation: Nymox Reports on U.S. Patent Issuancesfinanznachrichten.de - July 18 at 3:50 PMNymox Reports on U.S. Patent Issuancesfinance.yahoo.com - July 18 at 3:50 PMThe Committee to Restore Nymox Shareholder Value Soundly Rebuts Injurious Allegations Made by Nymox Pharmaceutical Corp Current Managementventurebeat.com - July 16 at 8:00 PMNymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of ...bakersfield.com - July 13 at 11:18 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsARCA biopharmaNASDAQ:ABIOARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Achieve Life SciencesNASDAQ:ACHVAchieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.Nymox PharmaceuticalNASDAQ:NYMXNymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.